Perioperative myocardial infarction in a patient receiving low-dose prothrombin complex concentrates

Thrombosis and Haemostasis

Volumn 98, Issue 5, 2007, Pages 1141-1142

  Bagot, Catherine N ^a   Cregg, Roman ^a   Patel, Raj K ^a   Shariff, Amina ^a   Arya, Roopen ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; PROTHROMBIN COMPLEX; VITAMIN K GROUP; WARFARIN;

ACUTE HEART INFARCTION; ADULT; ANAMNESIS; ARTICLE; ATHEROSCLEROSIS; AUTOPSY; CARDIOPULMONARY INSUFFICIENCY; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; COLON RESECTION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG SAFETY; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INTESTINE PERFORATION; LAPAROTOMY; LOW DRUG DOSE; MALE; PARTIAL THROMBOPLASTIN TIME; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; SEPSIS; THROMBOSIS;

BLOOD COAGULATION FACTORS; FATAL OUTCOME; HUMANS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 36049047110     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-04-0263     Document Type: Article

References (16)

1. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition - 2005 update. Br J Haematol 2005; 132: 277-285.
2. Boulis NB, Bobek MP, Schmaier A, et al. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1119.
3. Cartmill M, Dolan G, Byrne JL, et al. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergency. Br J Neurosurg 2000; 14: 458-461.
4. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anti-coagulation after intracerebral hemorrhage. Stroke 1992; 23: 972-977.
5. Van Aart L, Eijkhout HW, Kamphuis JS, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial. Thromb Res 2006; 118: 313-320.
6. Yasaka M, Sakata T, Naritomi H, et al. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005; 115: 455-459.
7. Kasper CK. Thromboembolic complications - Task Force Report. Thromb Diath Haemorrh 1975; 33: 640-644.
8. Aledort LM. Factor IX and thrombosis. Scand J Haematol 1977; 30 (Suppl): 40-42.
9. Magner A, Aronson D. Toxicity of factor IX conccentrates in mice. Dev Biol Stand 1979; 44:185-188.
10. Kohler M, Heiden M, Harbauer G, et al. Comparison of different prothrombin complex concentrates: In vitro and in vivo studies. Thromb Res 1990; 60: 63-70.
11. Seligsohn U, Kasper CK, Osterud B, et al. Activated factor VII: Presence in factor IX concentrates and persistence in the circulation after infusion. Blood 1979; 53: 828-837.
12. Gray E, Tubbs J, Thomas S, et al. Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity. Thromb Haemost 1995; 73: 675-679.
13. Hellstern P, Kohler M. Prothrombin complex conentrates (PCC) and thromboembolic complications. Ann Hematol 1995; 70 (Suppl I): A88.
14. Lusher JM. Prediction and management of adverse events associated with the use of factor IX complex concentrates. Semin Hematol 1993; 30 (2 SuppI 1): 36-40.
15. Reiss HB, Meier-Hellmann A, Motsch J, et al. Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007; in press.
16. Girolami G, Ruzzon E, Fabris F, et al. Myocardial infarction and other arterial occlusions in haemophilia A patients. Acta Haematol 2006; 116: 120-125.